Inhibikase Therapeutics

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

H.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug status

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

WILMINGTON, Del., July 23, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to its lead product candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of PAH. "The grant of Orphan Drug Designation for IKT-001 by FDA is ano

Exclusive BAC Article: Inhibikase Therapeutics; Ph 3 IMPROVE-PAH First Patient Dosed, Imatinib Prior Success From IMPRES Study, 2029 Potential Data Release, And Catalysts (NASDAQ:IKT)

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today announced that it has sold 25,000,000 shares of the Company’s common stock to RA Capital Management through its at-the-market (“ATM”) facility for gross proceeds of $50 million. The Company expects that the additional capital raised through this financing, together